Cargando…

The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles

Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Nearly 50% of the patients who receive the most intensive treatment develop chemoresistant leukemia relapse. Although the leukemogenic events leading to relapse seem to differ between patients (i.e., regrowth from a clone detect...

Descripción completa

Detalles Bibliográficos
Autores principales: Aasebø, Elise, Berven, Frode S., Hovland, Randi, Døskeland, Stein Ove, Bruserud, Øystein, Selheim, Frode, Hernandez-Valladares, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352627/
https://www.ncbi.nlm.nih.gov/pubmed/32512867
http://dx.doi.org/10.3390/cancers12061466
_version_ 1783557682228101120
author Aasebø, Elise
Berven, Frode S.
Hovland, Randi
Døskeland, Stein Ove
Bruserud, Øystein
Selheim, Frode
Hernandez-Valladares, Maria
author_facet Aasebø, Elise
Berven, Frode S.
Hovland, Randi
Døskeland, Stein Ove
Bruserud, Øystein
Selheim, Frode
Hernandez-Valladares, Maria
author_sort Aasebø, Elise
collection PubMed
description Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Nearly 50% of the patients who receive the most intensive treatment develop chemoresistant leukemia relapse. Although the leukemogenic events leading to relapse seem to differ between patients (i.e., regrowth from a clone detected at first diagnosis, progression from the original leukemic or preleukemic stem cells), a common characteristic of relapsed AML is increased chemoresistance. The aim of the present study was to investigate at the proteomic level whether leukemic cells from relapsed patients present overlapping molecular mechanisms that contribute to this chemoresistance. We used liquid chromatography–tandem mass spectrometry (LC–MS/MS) to compare the proteomic and phosphoproteomic profiles of AML cells derived from seven patients at the time of first diagnosis and at first relapse. At the time of first relapse, AML cells were characterized by increased levels of proteins important for various mitochondrial functions, such as mitochondrial ribosomal subunit proteins (MRPL21, MRPS37) and proteins for RNA processing (DHX37, RNA helicase; RPP40, ribonuclease P component), DNA repair (ERCC3, DNA repair factor IIH helicase; GTF2F1, general transcription factor), and cyclin-dependent kinase (CDK) activity. The levels of several cytoskeletal proteins (MYH14/MYL6/MYL12A, myosin chains; VCL, vinculin) as well as of proteins involved in vesicular trafficking/secretion and cell adhesion (ITGAX, integrin alpha-X; CD36, platelet glycoprotein 4; SLC2A3, solute carrier family 2) were decreased in relapsed cells. Our study introduces new targetable proteins that might direct therapeutic strategies to decrease chemoresistance in relapsed AML.
format Online
Article
Text
id pubmed-7352627
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73526272020-07-21 The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles Aasebø, Elise Berven, Frode S. Hovland, Randi Døskeland, Stein Ove Bruserud, Øystein Selheim, Frode Hernandez-Valladares, Maria Cancers (Basel) Communication Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Nearly 50% of the patients who receive the most intensive treatment develop chemoresistant leukemia relapse. Although the leukemogenic events leading to relapse seem to differ between patients (i.e., regrowth from a clone detected at first diagnosis, progression from the original leukemic or preleukemic stem cells), a common characteristic of relapsed AML is increased chemoresistance. The aim of the present study was to investigate at the proteomic level whether leukemic cells from relapsed patients present overlapping molecular mechanisms that contribute to this chemoresistance. We used liquid chromatography–tandem mass spectrometry (LC–MS/MS) to compare the proteomic and phosphoproteomic profiles of AML cells derived from seven patients at the time of first diagnosis and at first relapse. At the time of first relapse, AML cells were characterized by increased levels of proteins important for various mitochondrial functions, such as mitochondrial ribosomal subunit proteins (MRPL21, MRPS37) and proteins for RNA processing (DHX37, RNA helicase; RPP40, ribonuclease P component), DNA repair (ERCC3, DNA repair factor IIH helicase; GTF2F1, general transcription factor), and cyclin-dependent kinase (CDK) activity. The levels of several cytoskeletal proteins (MYH14/MYL6/MYL12A, myosin chains; VCL, vinculin) as well as of proteins involved in vesicular trafficking/secretion and cell adhesion (ITGAX, integrin alpha-X; CD36, platelet glycoprotein 4; SLC2A3, solute carrier family 2) were decreased in relapsed cells. Our study introduces new targetable proteins that might direct therapeutic strategies to decrease chemoresistance in relapsed AML. MDPI 2020-06-04 /pmc/articles/PMC7352627/ /pubmed/32512867 http://dx.doi.org/10.3390/cancers12061466 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Aasebø, Elise
Berven, Frode S.
Hovland, Randi
Døskeland, Stein Ove
Bruserud, Øystein
Selheim, Frode
Hernandez-Valladares, Maria
The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles
title The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles
title_full The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles
title_fullStr The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles
title_full_unstemmed The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles
title_short The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles
title_sort progression of acute myeloid leukemia from first diagnosis to chemoresistant relapse: a comparison of proteomic and phosphoproteomic profiles
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352627/
https://www.ncbi.nlm.nih.gov/pubmed/32512867
http://dx.doi.org/10.3390/cancers12061466
work_keys_str_mv AT aasebøelise theprogressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT bervenfrodes theprogressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT hovlandrandi theprogressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT døskelandsteinove theprogressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT bruserudøystein theprogressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT selheimfrode theprogressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT hernandezvalladaresmaria theprogressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT aasebøelise progressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT bervenfrodes progressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT hovlandrandi progressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT døskelandsteinove progressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT bruserudøystein progressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT selheimfrode progressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles
AT hernandezvalladaresmaria progressionofacutemyeloidleukemiafromfirstdiagnosistochemoresistantrelapseacomparisonofproteomicandphosphoproteomicprofiles